MFA
BNTX icon

Morling Financial Advisors’s BioNTech BNTX Stock Holding History

Morling Financial Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,700
Closed -$253K – 71
2022
Q2 		$253K Sell
1,700
-1,200
-41% -$183K 0.33% 41
2022
Q1 		$495K Buy
+2,900
New +$487K 0.63% 27

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morling Financial Advisors's BNTX Position: Q3 2022 in Review

Morling Financial Advisors sold out of BioNTech (BNTX) in Q3 2022, closing a stake of 1,700 shares — an estimated $253K sold.

Morling Financial Advisors first reported a position in BNTX in Q1 2022 and held it in 2 quarters. The position peaked at $495K in Q1 2022. 264 funds tracked by Wall St. Rank hold BNTX as of Q3 2022.

  • Morling Financial Advisors reported no remaining BioNTech position as of Q3 2022 after selling out during the quarter.
  • Morling Financial Advisors sold 1,700 BioNTech shares in Q3 2022, an estimated $253K.
  • Morling Financial Advisors first reported a position in BioNTech in Q1 2022 and held it in 2 quarters.
  • Morling Financial Advisors's BioNTech position peaked at $495K in Q1 2022.
  • 264 funds tracked by Wall St. Rank held BioNTech as of Q3 2022.

Based on Morling Financial Advisors's 13F filing for Q3 2022, filed 1 Nov 2022.